Therapy discontinuations related to side effects with the use of antitumour necrosis factor treatments in patients with chronic rheumatic diseases

Trial Profile

Therapy discontinuations related to side effects with the use of antitumour necrosis factor treatments in patients with chronic rheumatic diseases

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top